Observational Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Feb 28, 2023; 29(8): 1344-1358
Published online Feb 28, 2023. doi: 10.3748/wjg.v29.i8.1344
Table 5 Comparison of general data between patients with cervical cancer with severe acute radiation enteritis or no severe acute radiation enteritis
Factor
SARE (n = X)
No SARE (n = X)
OR (95%CI)
P value
Median (IQR)Median (IQR)
Clinical factors
Elderly (> 60 yr)/young and middle-aged (20-60 yr)0.123 (0.015-1.040)0.054
Age47.5 (37.0-54.0)53.0 (46.0-63.0)0.930 (0.872-0.992)0.027
Weight53.0 (51.0-60.9)56.0 (50.0-61.8)0.983 (0.918-1.054)0.631
BMI/kg/m220.5 (19.7-22.2)21.9 (20.4-23.0)0.936 (0.746-1.174)0.566
ACCI (2-3/4-5)0.123 (0.015-1.040)0.054
Tumor type (squamous/non-squamous)0.848 (0.139-5.179)0.859
T (> 4 cm/≤ 4 cm)0.510 (0.153-1.695)0.272
N (positive/negative)0.615 (0.165-2.298)0.538
Metastatic pelvic lymph nodes (positive/negative)0.694 (0.185-2.611)0.589
Common iliac lymph node metastasis (positive/negative)0.427 (0.046-3.980)0.455
Para-aortic lymph nodes (positive/negative)1.471 (1.216-1.779)0.999
FIGO stage (IIB-IVA/IB-IIA)1.108 (0.328-3.739)0.869
LVSI (positive/negative)0.548 (0.147-2.034)0.368
Differentiation degree (low and medium differentiation/high differentiation)1.011 (0.225-4.536)0.988
Infiltration degree (shallow 1/3/medium depth 1/3)0.837 (0.191-3.673)0.813
Incisal margin (R1 + R2/R0)0.427 (0.046-3.980)0.455
Risk (low risk/medium high risk)1.227 (0.340-4.242)0.754
HPV (positive/negative)1.324 (0.127-13.785)0.815
SCC (abnormally elevated/not abnormal)0.303 (0.074-1.245)0.098
Surgery (performed/not performed)2.080 (0.497-8.706)0.316
CCRT (implemented/not implemented)6.042 (1.681-21.718)0.006
Myelosuppression (Grade 1-3/Grade 0)0.617 (0.178-2.144)0.446
Diarrhea (Grade 1-3/Grade 0)NA0.999
Abdominal pain (Grade 1-3/Grade 0)25.375 (4.750-135.559)< 0.001
Colitis (Grade 1-3/Grade 0)38.500 (6.530-226.993)< 0.001
Anal bulge (Grade 1-3/Grade 0)5.185 (1.470-18.286)0.010
Hematochezia (Grade 1-3/Grade 0)NA< 0.001
DAI score2.8 (2.3-3.0)1.7 (1.2-2.0)152.546 (6.045-3849.771)0.002
Physical dose parameters
Small intestine
V20 (%)80.9 (68.6-93.7)78.0 (66.8-82.5)1.015 (0.975-1.056)0.475
V25 (%)58.2 (46.0-62.9)52.0 (48.0-57.3)1.014 (0.955-1.076)0.659
V30 (%)41.0 (35.1-47.6)39.6 (31.1-42.1)1.039 (0.961-1.122)0.335
V35 (%)29.6 (23.5-32.2)26.9 (24.4-29.1)1.032 (0.927-1.149)0.569
V40 (%)19.5 (16.8-23.3)19.3 (13.3-20.7)1.068 (0.928-1.229)0.358
Rectum
V20 (%)80.9 (68.6-93.7)78.0 (66.8-82.5)1.015 (0.975-1.056)0.475
V25 (%)58.2 (46.0-62.9)52.0 (48.0-57.3)1.014 (0.955-1.076)0.659
V30 (%)41.0 (35.1-47.6)39.6 (31.1-42.1)1.039 (0.961-1.122)0.335
V35 (%)29.6 (23.5-32.2)26.9 (24.4-29.1)1.032 (0.927-1.149)0.569
V40 (%)19.5 (16.8-23.3)19.3 (13.3-20.7)1.068 (0.928-1.229)0.358
Colon
V20 (%)100.0 (100.0-100.0)100.0 (100.0-100.0)NANA
V25 (%)100.0 (100.0-100.0)100.0 (100.0-100.0)NANA
V30 (%)100.0 (100.0-100.0)100.0 (100.0-100.0)0.982 (0.775-1.246)0.883
V35 (%)100.0 (99.1-100.0)100.0 (100.0-100.0)0.981 (0.915-1.052)0.981
V40 (%)80.4 (71.3-89.2)79.3 (72.1-87.8)1.005 (0.956-1.056)0.851
Femoral head
V20 (%)35.4 (19.7-57.3)48.6 (22.9-65.2)0.994 (0.971-1.017)0.586
V25 (%)24.8 (13.7-40.1)31.6 (16.0-45.1)0.996 (0.967-1.026)0.797
V30 (%)17.7 (9.8-29.6)22.6 (11.4-32.6)0.997 (0.957-1.039)0.877
V35 (%)13.3 (7.4-20.0)16.9 (8.6-24.5)0.989 (0.935-1.047)0.711
V40 (%)8.9 (4.9-14.3)11.3 (5.7-16.3)0.993 (0.916-1.076)0.858
Total pelvic lymphatic drainage dose (Gy)45.0 (45.0-45.0)45.0 (45.0-48.5)1.194 (0.877-1.625)0.261
Para-aortic extended field radiotherapy (performed/not performed)1.485 (1.222-1.804)0.999
ACCI: Adjusted Charlson Comorbidity Index; CCRT: Concurrent chemoradiotherapy; SCC: Squamous cell carcinoma; HPV: Human papillomavirus; NA: Not available; DAI: Disease activity index.